Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BioTRAC (BIOLOGIC TREATMENT REGISTRY ACROSS CANADA)

Next Previous
Trial Profile

BioTRAC (BIOLOGIC TREATMENT REGISTRY ACROSS CANADA)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golimumab (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms BioTRAC
  • Sponsors Janssen Inc; Merck & Co

Most Recent Events

  • 14 Nov 2022 Results describing the long-term incidence of infection of RA pts treated with GLM in routine care, assessing the impact of infections on GLM retention, and exploring risk factors associated with infection presented at the ACR Convergence 2022
  • 14 Nov 2022 Results of a post-hoc analysis assessing the risk of major adverse cardiovascular events (MACE), malignancy, and mortality in a large observational cohort of patients with RA, PsA, or axSpA treated with subcutaneous Golimumab, presented at the ACR Convergence 2022
  • 04 Jun 2022 Results (n=530) of a post-hoc analysis assessing long-term incidence of infection, impact of infections on Golimumab retention and exploring factors associated with risk of infection in a cohort of Rheumatoid Arthritis patients in Canadapresented at the 23rd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top